Business Description
Pharmaceuticals account for essentially all of revenue. The company's identity is infectious disease: the influenza antiviral Xofluza, the COVID-19 antiviral Xocova, and the antibiotic cefiderocol, developed for multidrug-resistant Gram-negative infections. Alongside that sits a pain and central-nervous-system franchise, and a vaccine and diagnostics effort. Shionogi does not sell HIV drugs itself — it contributed its HIV research to ViiV Healthcare, the venture majority-owned by GSK — but it holds an equity stake and receives royalties on ViiV's dolutegravir-based products.
That royalty stream is what makes Shionogi's earnings look different from a mid-sized pharma's: it arrives at very high margin and depends on ViiV's sales and on the patent life of the underlying drugs, so the market watches HIV market share and patent expiry dates as closely as it watches the company's own pipeline. Around seven-tenths of revenue comes from outside Japan, making the dollar and the yen direct earnings levers, while domestic drug-price revisions squeeze the home market on a fixed cycle. The business was founded in 1878 by Gisaburo Shiono in Osaka's Doshomachi medicine district, was incorporated in June 1919, and today runs its global headquarters from Grand Green Osaka while keeping an Osaka head office on the old Doshomachi site. The fiscal year ends in March.
Corporate Data
| Ticker | 4507 |
|---|---|
| Exchange | Tokyo Stock Exchange |
| Size Category | TOPIX Large70 |
| Market Segment | Prime Market |
| Sector | Pharmaceuticals |
| Head Office | Grand Green Osaka Park Tower, 5-54 Ofukacho, Kita-ku, Osaka 530-0011, Japan |
| Founded | June 5, 1919 |
| Fiscal Year End | March 31 |
| Website | Official website |